• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Anteris Technologies Global Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8/7/25 7:00:41 AM ET
    $AVR
    Industrial Specialties
    Health Care
    Get the next $AVR alert in real time by email
    false0002011514NASDAQ00020115142025-08-072025-08-07

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    FORM 8-K



    CURRENT REPORT
    Pursuant to Section 13 OR 15(d)
    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 7, 2025



    Anteris Technologies Global Corp.
    (Exact name of registrant as specified in its charter)



    Delaware
    001-42437
    99-1407174
    (State or Other Jurisdiction of Incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification No.)

    Toowong Tower, Level 3, Suite 302
    9 Sherwood Road
    Toowong, QLD
    Australia
     
    4066
    (Address of Principal Executive Offices)
     
    (Zip Code)

    Registrant’s telephone number, including area code: +61 7 3152 3200

    Not Applicable
    (Former name or former address, if changed since last report)



    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock, par value $0.0001 per share
     
    AVR
     
    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 8.01.
    Other Events.
     
    On August 7, 2025, Anteris Technologies Global Corp. (the “Company”) lodged an announcement with the  Australian Securities Exchange (“ASX”) regarding the Company’s receipt from the ASX of a waiver from ASX Listing Rule 7.1 (the “ASX Waiver”) on an ongoing basis. The ASX Waiver permits the Company to issue securities without stockholder approval under ASX Listing Rule 7.1, which generally restricts ASX-listed entities from issuing securities in excess of 15% of their issued share capital without stockholder approval over a 12-month period unless an exception applies. The Company will remain subject to the restrictions under the listing rules of The Nasdaq Stock Market (the “Nasdaq Listing Rules”) with respect to the issuance of new securities.
     
    The ASX Waiver is subject to the following terms and conditions:
     

    •
    the Company remains subject to, and complies with, the Nasdaq Listing Rules and relevant United States federal and state securities laws for Delaware corporations with respect to the issuance of new securities;


    •
    the grant of the ASX Waiver to the Company must be approved by a special resolution of the Company’s stockholders, which requires the affirmative vote of 75% of the votes cast;


    •
    the ASX Waiver will remain in force for a period of three years commencing on the date of the stockholder approval of the ASX Waiver;


    •
    the Company must include a statement in or with its full year financial statements that are provided to the ASX that summarizes the ASX Waiver and confirms that the Company remains subject to, and continues to comply with, the requirements of the Nasdaq Listing Rules and relevant United States federal and state securities laws for Delaware corporations with respect to the issuance of new securities. Prior to publishing this statement, the Company must confirm with ASX that there has been no change to ASX’s policy settings in relation to security holder approval requirements; and


    •
    the Company must immediately advise the ASX if the Company becomes aware of any change to the application of the Nasdaq Listing Rules or relevant United States federal and state securities laws for Delaware corporations with respect to the issuances of new securities, or that the Company is no longer in compliance with the requirements of the Nasdaq Listing Rules or the relevant United States federal and state securities laws for Delaware corporations with respect to the issuances of new securities.

    Without limiting ASX’s right to vary or revoke its decision pursuant to ASX Listing Rule 18.3, ASX reserves the right to revoke the ASX Waiver if:


    •
    the Company fails to comply with any of the conditions set forth above;


    •
    there are changes to the Nasdaq Listing Rules concerning the issuance of new securities; or


    •
    there are changes to ASX’s policy settings in relation to security holder approval requirements arising from the current review of those settings or any subsequent review.
     
    A copy of the ASX announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
     
    Item 9.01.
    Financial Statements and Exhibits
     
    (d)
    Exhibits.

    The following exhibits are filed with this Current Report on Form 8-K:

    Exhibit
    No.
     
    Description
    99.1
     
    ASX Announcement: Waiver from ASX Listing Rule 7.1
         
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    Anteris Technologies Global Corp.
       
    Date: August 7, 2025
       
         
     
    By:
    /s/ Wayne Paterson
     
    Name:
    Wayne Paterson
     
    Title:
    Chief Executive Officer, Vice Chairman



    Get the next $AVR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVR

    DatePrice TargetRatingAnalyst
    1/8/2025$20.00Buy
    Lake Street
    1/7/2025$15.00Buy
    TD Cowen
    1/7/2025$9.00Overweight
    Cantor Fitzgerald
    1/7/2025$22.00Overweight
    Barclays
    More analyst ratings

    $AVR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anteris Announces Results for the Second Quarter of 2025

    MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercialising cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended June 30, 2025, and provided a corporate update. Second Quarter 2025 Highlights 130 patients implanted with the DurAVR® THV since the start of clinical development; 49 patients treated year-to-date; 21 in the quarterWorld first "double DurAVR®" implant in a patient receiving a valve-in-valve replacement in both the mitral and ao

    8/11/25 4:52:02 PM ET
    $AVR
    Industrial Specialties
    Health Care

    Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

    MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

    6/9/25 10:52:06 PM ET
    $AVR
    $LMAT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    Anteris Announces Results for the First Quarter of 2025

    MINNEAPOLIS and BRISBANE, Australia, May 13, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. First Quarter 2025 Highlights Investigational Device Exemption ("IDE") for the DurAVR® THV's global, pivotal clinical trial (the "PARADIGM Trial"), submitted to the FDA during the First QuarterScale up for commencement of the PARADIGM Trial ongoing – including expanding the Clinical S

    5/13/25 5:45:28 PM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Moss Gregory S.

    3 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    6/10/25 6:01:58 AM ET
    $AVR
    Industrial Specialties
    Health Care

    SEC Form 3 filed by new insider Roberts David B

    3 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    6/10/25 6:01:52 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Amendment: Director Seaberg John D exercised 40,000 shares at a strike of $7.13 and covered exercise/tax liability with 36,148 shares (SEC Form 4)

    4/A - Anteris Technologies Global Corp. (0002011514) (Issuer)

    3/21/25 9:30:47 AM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Anteris Technologies Global Corp. with a new price target

    Lake Street initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $20.00

    1/8/25 8:52:46 AM ET
    $AVR
    Industrial Specialties
    Health Care

    TD Cowen initiated coverage on Anteris Technologies Global Corp. with a new price target

    TD Cowen initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $15.00

    1/7/25 9:02:46 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Cantor Fitzgerald initiated coverage on Anteris Technologies Global Corp. with a new price target

    Cantor Fitzgerald initiated coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $9.00

    1/7/25 9:00:55 AM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    SEC Filings

    View All

    SEC Form DEF 14A filed by Anteris Technologies Global Corp.

    DEF 14A - Anteris Technologies Global Corp. (0002011514) (Filer)

    8/18/25 6:01:05 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Anteris Technologies Global Corp.

    SCHEDULE 13G/A - Anteris Technologies Global Corp. (0002011514) (Subject)

    8/14/25 4:23:36 PM ET
    $AVR
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Anteris Technologies Global Corp.

    SCHEDULE 13G/A - Anteris Technologies Global Corp. (0002011514) (Subject)

    8/13/25 2:00:06 PM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Leadership Updates

    Live Leadership Updates

    View All

    Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

    MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

    6/9/25 10:52:06 PM ET
    $AVR
    $LMAT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments